Power3 Medical to Publish Medical Breakthrough Documented During Clinical Trials of Power3 Medical's Flag Ship NuroPro® Diagnostic

Las Vegas (CRWENEWSWIRE)

*** FREE ""HOT"" Stock Alerts***
from CRWENEWSWIRE

It's Free and Easy Sign Up below

http://www.crwenewswire.com/signup

****************************************************

HOUSTON--(CRWENEWSWIRE)--Power3 Medical Products, Inc. (OTCBB: PWRM) announced today that, in collaboration with Lourdes R. Bosquez, MD, it has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro® protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept® (Donepezil HCl, Pfizer – NYSE: PFE), Exelon® (Rivastigmine, Novartis – NYSE: NVS), and Namenda® (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.

NuroPro® was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, NuroPro® now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.

Power3 has filed for patent protection for these findings and will be publishing these seminal results in the near future in one of the world’s most prestigious peer-reviewed scientific journals. Power3 also plans to demonstrate the clinical application and benefits of its NuroPro® diagnostic tests to healthcare providers located throughout the world. Power3 believes that this will assist the company greatly in an effort to generate sales of its NuroPro® diagnostic tests. Power3 is currently working on a joint distribution effort with a number of potential business partners, such as the companies mentioned above, for the sale of its NuroPro® diagnostic tests and the development of new drugs.

“This new and amazing discovery will help clarify some of the clinical observations and overcome difficulties that we have had as physicians, not only by helping us choose more appropriate treatment and better predict response, but also by helping us find more permanent treatments for the dementias,” said Dr. Bosquez.

Ira L. Goldknopf, Ph.D., President and Chief Scientific Officer of Power3, stated, “This innovation will provide physicians with an invaluable perspective to use in the treatment of their patients and will have profound implications for the diagnosis and treatment of Alzheimer’s disease, and for other diseases as well.”

Lourdes R. Bosquez, MD

Lourdes R. Bosquez, MD, PA is a child, adolescent, adult & geriatric psychiatrist in The Woodlands, Texas. Dr. Bosquez has a large private practice as well as 3 Medical Directorships in Psychiatry. Her current work in the last 9 years has been in dementia at: Cy Fair Medical Hospital, Tomball Texas; Methodist Hospital Willowbrook, Texas; and Directions of Recovery, a substance abuse program. She is a consultant to several large drug companies. Some of her research work includes “Diagnosing Depression in Cancer Children.” She presents papers at a many national neurological meetings. Dr. Bosquez is active in community functions and participates in training and education.

Dr. Bosquez received her MD from Autonomous U. of Nuevo Leon School of Medicine in Monterrey, Mexico with honors, and then did her Psychiatry and Neurology training at the University of Texas Health Science Center, Houston, Texas, where she was elected Chief Resident. She also did a Fellowship in Child and Adolescent Psychiatry at UTHSC. She is a member of American Board of Forensic Medicine, American Academy of Pain Management, American Board of Disability, American Child & Adolescent Psychiatry Association, American Psychiatry Association, Texas Medical Association, and Harris County Medical Association.

Power3 Medical Products

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro^™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro^®, a serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, currently engaged in Phase II clinical trials. These products are designed to analyze proteins and their mutations to assess an individual’s risk for developing disease later in life, a patient’s likelihood of responding to a particular drug, a patient’s risk of disease progression and disease recurrence, to measure a patient’s exposure to drug therapy, to ensure optimal dosing and reduced drug toxicity.

For more information, please visit http://www.power3medical.com.

Safe Harbor Provision

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained herein, including, without limitation, statements regarding the company's future financial position, business strategy, budgets, projected revenues and costs, and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expects," "intends," "plans," "projects," "estimates," "anticipates," or "believes" or the negative thereof or any variation thereon or similar terminology or expressions. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from results proposed in such statements. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can provide no assurance that such expectations will prove to have been correct. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2009 and its other filings and submissions with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, the company assumes no obligation to update or revise any of the information contained in this press release.

Crown Equity Holdings, Inc.
Ken Bosket, 877-854-6797 or 702-448-1543

****************************************************

***FREE STOCK ALERTS***

CRWENEWSWIRE, Your destination for stock alerts, stock news and more covering the exciting NASDAQ, NYSE, AMEX, OTC and other exchanges. Our members receive stock alerts via email so don’t forget to sign up. It’s easy and FREE. (Click on the Link Below)

http://www.crwenewswire.com/signup

Forward Looking Statement This press release contains forward- looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.

****************************************************

About CRWENewswire.com

CRWENewswire.com is an independent electronic informative online financial news publication company dedicated in providing company associates, business and financial professionals with economic and investment information, as well as stock highlights. CRWENewswire.com is a division of Crown Equity Holdings, Inc.

CRWENewswire.com is not a registered investment advisor or broker-dealer. CRWENewswire.com and Crown Equity Holdings, Inc., (CRWE) affiliates, officers, directors, contractors and employees, including may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)

We encourage investors to join and receive CRWENewswire.comFREE e-mail news and stock watch alerts at http://www.crwenewswire.com/signup